| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UROS |
| Uniprot No | P10746 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-265aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMKVLLLKDAKEDDCGQDPYIRELGLYGLEA TLIPVLSFEFLSLPSFSEKLSHPEDYGGLIFTSPRAVEAAELCLEQNNKT EVWERSLKEKWNAKSVYVVGNATASLVSKIGLDTEGETCGNAEKLAEYIC SRESSALPLLFPCGNLKREILPKALKDKGIAMESITVYQTVAHPGIQGNL NSYYSQQGVPASITFFSPSGLTYSLKHIQELSGDNIDQIKFAAIGPTTAR ALAAQGLPVSCTAESPTPQALATGIRKALQPHGCC |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于UROS(尿卟啉原III合成酶)重组蛋白的文献概览，涵盖其重组表达、结构研究及治疗应用：
---
1. **文献名称**: *Recombinant expression and characterization of human uroporphyrinogen III synthase*
**作者**: Sardh, E., Harper, P., Andersson, D.E.
**摘要**: 本研究在大肠杆菌中成功表达并纯化了重组人源UROS蛋白，优化了表达条件以提高酶活性。通过体外实验验证其催化尿卟啉原III合成的能力，为卟啉症相关研究提供了功能活性蛋白工具。
---
2. **文献名称**: *Structural insights into the catalytic mechanism of uroporphyrinogen III synthase*
**作者**: Phillips, J.D., Whitby, F.G., Warren, M.J.
**摘要**: 通过X射线晶体学解析了重组UROS的三维结构，揭示了其与底物结合的关键位点及催化机制，为开发针对先天性红细胞生成性卟啉症(CEP)的酶替代疗法奠定结构基础。
---
3. **文献名称**: *Gene therapy for congenital erythropoietic porphyria using recombinant UROS*
**作者**: Fontanellas, A., Blouin, J.M., Ged, C.
**摘要**: 研究利用重组UROS在HEK293细胞中表达，通过慢病毒载体递送至CEP患者细胞，证实其可纠正酶缺陷并减少卟啉积累，为基因治疗提供了潜在策略。
---
4. **文献名称**: *Enzyme replacement therapy in a murine model of porphyria using recombinant UROS*
**作者**: Yasuda, M., Desnick, R.J., Balwani, M.
**摘要**: 在小鼠模型中评估重组UROS的酶替代治疗效果，结果显示皮下注射可显著降低肝脏和血液中的毒性卟啉水平，支持其作为CEP的临床治疗候选方案。
---
**备注**：以上文献标题和内容为示例性概括，实际研究中需根据具体需求检索PubMed等数据库获取准确信息。
**Background of UROS Recombinant Protein**
Uroporphyrinogen III synthase (UROS) is a critical enzyme in the heme biosynthesis pathway, catalyzing the conversion of hydroxymethylbilane (HMB) to uroporphyrinogen III, a key precursor of heme and chlorophyll. This enzymatic step is essential for maintaining cellular homeostasis, as heme is a prosthetic group in hemoglobin, cytochromes, and other oxygen-binding proteins. Mutations in the *UROS* gene lead to congenital erythropoietic porphyria (CEP), a rare autosomal recessive disorder characterized by severe cutaneous photosensitivity, hemolytic anemia, and accumulation of non-physiological porphyrins.
Recombinant UROS protein has emerged as a therapeutic candidate for CEP and related porphyrias. Produced via genetic engineering in heterologous systems (e.g., *E. coli* or mammalian cells), recombinant UROS aims to restore enzymatic activity in deficient patients. Early studies focused on enzyme replacement therapy (ERT), leveraging recombinant UROS to reduce toxic porphyrin accumulation. However, challenges such as short enzyme half-life and immune responses prompted alternative strategies, including gene therapy. For instance, lentiviral or adeno-associated virus (AAV)-mediated delivery of functional *UROS* has shown promise in preclinical models.
Beyond therapeutics, recombinant UROS is used *in vitro* to study heme biosynthesis mechanisms, screen modulators of enzymatic activity, and develop diagnostic assays for porphyria subtypes. Its high purity and specificity make it valuable for structural studies, elucidating mutation-induced conformational changes.
Recent advancements include engineered UROS variants with enhanced stability and catalytic efficiency, as well as hybrid approaches combining ERT with chaperone molecules. Clinical trials for UROS-targeted therapies remain limited but highlight potential for addressing unmet needs in CEP management. Overall, recombinant UROS represents a bridge between understanding porphyria pathophysiology and developing precision medicine solutions.
×
